Summary
Pfizer Inc.'s 1993 10-K filing, made in March 1994, provides a snapshot of the company's financial performance and operational landscape as of the fiscal year ending December 30, 1993. As a leading pharmaceutical company, Pfizer's core business revolves around the research, development, manufacturing, and marketing of a diverse range of healthcare products, including prescription medicines, agricultural products, and consumer healthcare items. Investors should note that this period predates many of the blockbuster drug launches and significant market expansions that characterized later years for Pfizer. The filing would detail their product portfolio, geographical sales breakdown, and investments in research and development, which are critical indicators of future growth potential. Understanding Pfizer's strategic priorities and financial health in 1993 offers valuable context for evaluating its long-term trajectory and the competitive environment it operated within.
Key Highlights
- 1Pfizer Inc. filed its 10-K annual report for the fiscal year ending December 30, 1993, on March 24, 1994.
- 2The company operates in the pharmaceutical sector, focusing on research, development, manufacturing, and marketing of healthcare products.
- 3Pfizer's business segments likely include prescription medicines, agricultural products, and consumer healthcare.
- 4The filing provides a detailed look at Pfizer's financial performance and operational activities for 1993.
- 5Key areas for investor focus would be R&D investment, product sales, and international market presence.
- 6This filing offers historical context for Pfizer's growth and market position in the mid-1990s.
- 7The SEC EDGAR database served as the platform for this public filing.